279221-23-7

Upstream product

• 28033-37-6 4-[4-(trifluoromethyl)-phenoxy]piperidine 
• 23095-31-0 3,4-dimethoxybenzene-1-sulfonyl chloride 
• 308386-22-3 2,3-dimethoxy-N-(tetrahydro-pyran-2-yloxy)-6-[4-(4-trifluoromethyl-phenoxy)-piperidine-1-sulfonyl]-benzamide 
• 308386-21-2 2,3-dimethoxy-6-[4-(4-trifluoromethyl-phenoxy)-piperidine-1-sulfonyl]-benzoic acid 
• 308386-20-1 1-(3,4-dimethoxy-benzenesulfonyl)-4-(4-trifluoromethyl-phenoxy)-piperidine 

Relevant academic research and scientific papers

Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors

This invention is directed to a process for inhibiting aggrecanase activity. The process comprises administering a therapeutically effective amount of a sulfonyl aromatic or heteroaromatic hydroxamic acid, a derivative thereof, or a pharmaceutically acceptable salt of the hydroxamic acid or derivative to a host animal. The compound generally corresponds in structure to the following formula: wherein W and the R groups are described in more detail in Applicants' specification.

Sulfonyl aryl or heteroaryl hydroxamic acid compounds

A sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.

Selective, orally active MMP inhibitors with an aryl backbone

This letter describes SAR exploration and rat PK optimization of a series of novel, MMP-1 sparing aryl hydroxamate sulfonamides with activity against MMP-2 and MMP-13.